Analyst Says Acelyrin (SLRN) Dosing Errors Create “Too Much Uncertainty,” Securities Class Action Pending – Hagens Berman
SAN FRANCISCO, Jan. 07, 2024 (GLOBE NEWSWIRE) — Hagens Berman urges Acelyrin, Inc. (NASDAQ: SLRN) investors who suffered substantial losses to submit your losses now. Class Period: May 4, 2023